* FY15 sales increased by 11%, including Vifor Pharma (25% of sales) +36.9% and Galenica Santé +3.9%. * The spin-off into two independent companies could be take place from the Q4 2016.
27 Jan 2016
Vifor Pharma's strong growth driven by Mircera
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Vifor Pharma's strong growth driven by Mircera
Galenica AG (0ROG:LON) | 0 0 0.0% | Mkt Cap: 2,446m
- Published:
27 Jan 2016 -
Author:
Armelle Moulin -
Pages:
2
* FY15 sales increased by 11%, including Vifor Pharma (25% of sales) +36.9% and Galenica Santé +3.9%. * The spin-off into two independent companies could be take place from the Q4 2016.